Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis (Q44960748)

7 December 2017

Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis (English)

1 reference

7 December 2017

2

1 reference

7 December 2017

6

David Dingli

1 reference

7 December 2017

3

Martha Q Lacy

1 reference

7 December 2017

9

Morie A Gertz

1 reference

7 December 2017

4

Suzanne R Hayman

1 reference

7 December 2017

5

Francis K Buadi

1 reference

7 December 2017

7

Shaji K Kumar

1 reference

7 December 2017

Stefan Cordes

1

1 reference

PubMed ID

22707405

7 December 2017

William J Hogan

series ordinal

8

1 reference

PubMed ID

22707405

7 December 2017

language of work or name

English

0 references

publication date

15 June 2012

1 reference

7 December 2017

1 reference

7 December 2017

118

1 reference

7 December 2017

24

1 reference

7 December 2017

6105-6109

1 reference

7 December 2017

The systemic amyloidoses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27660

Amyloidosis: pathogenesis and new therapeutic options.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27660

Molecular mechanisms of amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27660

Membrane interaction of islet amyloid polypeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27660

Kinetics of amyloid formation and membrane interaction with amyloidogenic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27660

Membrane damage by human islet amyloid polypeptide through fibril growth at the membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27660

Amyloid aggregation on lipid bilayers and its impact on membrane permeability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27660

Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27660

Improved survival in multiple myeloma and the impact of novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27660

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27660

Transplantation vs. conventional-dose therapy for amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27660

Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27660

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27660

Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27660

Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27660

Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27660

Cox's Regression Model for Counting Processes: A Large Sample Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27660

Illuminating folding intermediates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27660

7 January 2021

A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27660

7 January 2021

Nutritional status of outpatients with systemic immunoglobulin light-chain amyloidosis 1

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27660

7 January 2021

Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27660

7 January 2021

Identifiers

DOI

10.1002/CNCR.27660

1 reference

7 December 2017

1 reference

PubMed ID

22707405